News

Studie: Behandlung der metabolischen Azidose bei Nierentransplantierten.

Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomized, single-blind, placebo-controlled, phase 3 trial

Prof Nilufar Mohebbi, MD Alexander Ritter, MD Anna Wiegand, PhD Nicole Graf, PhD Suzan Dahdal, MD Daniel Sidler, MD Prof Spyridon Arampatzis, MD Karine Hadaya, MD Prof Thomas F Mueller, MD Prof Carsten A Wagner, MD Prof Rudolf P Wüthrich, MD

Metabolische Azidose kommt bei Nierentransplantierten relativ häufig vor und kann potenzial die Funktion der transplantierten Niere beeinträchtigen. Es wird zwar angenommen, dass eine Behandlung mit Natriumbikarbonat, die Azidose korrigieren kann, aber es gab bis kurzem keine randomisierte Studie, die untersucht haben, ob eine solche Behandlung langfristig die Nierenfunktion erhalten oder sogar verbessern kann. In dieser Studie aus der Schweiz, veröffentlicht im “Lancet”, einer führenden medizinischen Fachzeitschrift, wurde erstmal gezeigt, dass eine zweijährige Behandlung mit Natriumbikarbonat bei Nierentransplantierten keinen messbaren Einfluss auf die Nierenfunktion, gemessen an der glomerulären Filtrationsrate (GFR), hatte.

Background

Metabolic acidosis is common in kidney transplant recipients and is associated with declining graft function. Sodium bicarbonate treatment effectively corrects metabolic acidosis, but no prospective studies have examined its effect on graft function. Therefore, we aimed to test whether sodium bicarbonate treatment would preserve graft function and slow the progression of estimated glomerular filtration rate (GFR) decline in kidney transplant recipients.

Methods

The Preserve-Transplant Study was a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial at three University Hospitals in Switzerland (Zurich, Bern, and Geneva), which recruited adult (aged ≥18 years) male and female long-term kidney transplant recipients if they had undergone transplantation more than 1 year ago. Key inclusion criteria were an estimated GFR between 15 mL/min per 1·73 m2 and 89 mL/min per 1·73 m2, stable allograft function in the last 6 months before study inclusion (<15% change in serum creatinine), and a serum bicarbonate of 22 mmol/L or less. We randomly assigned patients (1:1) to either oral sodium bicarbonate 1·5–4·5 g per day or matching placebo using web-based data management software. Randomisation was stratified by study centre and gender using a permuted block design to guarantee balanced allocation. We did multi-block randomisation with variable block sizes of two and four. Treatment duration was 2 years. Acid-resistant soft gelatine capsules of 500 mg sodium bicarbonate or matching 500 mg placebo capsules were given at an initial dose of 500 mg (if bodyweight was <70 kg) or 1000 mg (if bodyweight was ≥70 kg) three times daily. The primary endpoint was the estimated GFR slope over the 24-month treatment phase. The primary efficacy analyses were applied to a modified intention-to-treat population that comprised all randomly assigned participants who had a baseline visit. The safety population comprised all participants who received at least one dose of study drug. The trial is registered with ClinicalTrials.govNCT03102996.

Findings

Between June 12, 2017, and July 10, 2019, 1114 kidney transplant recipients with metabolic acidosis were assessed for trial eligibility. 872 patients were excluded and 242 were randomly assigned to the study groups (122 [50%] to the placebo group and 120 [50%] to the sodium bicarbonate group). After secondary exclusion of two patients, 240 patients were included in the intention-to-treat analysis. The calculated yearly estimated GFR slopes over the 2-year treatment period were a median –0·722 mL/min per 1·73 m2 (IQR –4·081 to 1·440) and mean –1·862 mL/min per 1·73 m2 (SD 6·344) per year in the placebo group versus median –1·413 mL/min per 1·73 m2 (IQR –4·503 to 1·139) and mean –1·830 mL/min per 1·73 m2 (SD 6·233) per year in the sodium bicarbonate group (Wilcoxon rank sum test p=0·51; Welch t-test p=0·97). The mean difference was 0·032 mL/min per 1·73 m2 per year (95% CI –1·644 to 1·707). There were no significant differences in estimated GFR slopes in a subgroup analysis and a sensitivity analysis confirmed the primary analysis. Although the estimated GFR slope did not show a significant difference between the treatment groups, treatment with sodium bicarbonate effectively corrected metabolic acidosis by increasing serum bicarbonate from 21·3 mmol/L (SD 2·6) to 23·0 mmol/L (2·7) and blood pH from 7·37 (SD 0·06) to 7·39 (0·04) over the 2-year treatment period. Adverse events and serious adverse events were similar in both groups. Three study participants died. In the placebo group, one (1%) patient died from acute respiratory distress syndrome due to SARS-CoV-2 and one (1%) from cardiac arrest after severe dehydration following diarrhoea with hypotension, acute kidney injury, and metabolic acidosis. In the sodium bicarbonate group, one (1%) patient had sudden cardiac death.

Interpretation

In adult kidney transplant recipients, correction of metabolic acidosis by treatment with sodium bicarbonate over 2 years did not affect the decline in estimated GFR. Thus, treatment with sodium bicarbonate should not be generally recommended to preserve estimated GFR (a surrogate marker for graft function) in kidney transplant recipients with chronic kidney disease who have metabolic acidosis.

Funding

Swiss National Science Foundation.